Jinling Pharmaceutical Company Limited (SHE:000919)

Market Cap	5.34B +26.6%
Revenue (ttm)	3.20B -2.6%
Net Income	53.91M +33.4%
EPS	0.09 +27.1%
Shares Out	621.92M
PE Ratio	98.96
Forward PE	n/a
Dividend	0.10 (1.12%)
Ex-Dividend Date	Jul 8, 2025

Volume	185,482,452
Average Volume	22,175,751
Open	7.36
Previous Close	8.91
Day's Range	7.36 - 9.80
52-Week Range	5.90 - 9.80
Beta	0.43
RSI	77.49
Earnings Date	Mar 31, 2026

About SHE:000919

Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China and internationally. The company offers Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, multiple arteriosclerosis, phlebitis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, and thrombophlebitis, etc., as well as cardiovascular and cerebrovascular diseases; Sulifei ferrous aluminate tablets for the prevention and treatment of...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 5,789
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000919

Financial Performance

In 2025, SHE:000919's revenue was 3.20 billion, a decrease of -2.56% compared to the previous year's 3.28 billion. Earnings were 53.91 million, an increase of 33.42%.